Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Stock Position Trimmed by Missouri Trust & Investment Co

Missouri Trust & Investment Co decreased its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 5.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 11,365 shares of the medical equipment provider’s stock after selling 670 shares during the period. Missouri Trust & Investment Co’s holdings in Zimmer Biomet were worth $1,200,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently made changes to their positions in the company. Geode Capital Management LLC lifted its stake in shares of Zimmer Biomet by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after acquiring an additional 125,852 shares during the period. M&T Bank Corp lifted its position in Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after purchasing an additional 8,709 shares during the period. National Pension Service boosted its stake in Zimmer Biomet by 3.8% during the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock valued at $39,893,000 after purchasing an additional 13,612 shares in the last quarter. Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter valued at $654,000. Finally, River Global Investors LLP raised its stake in shares of Zimmer Biomet by 31.3% in the 3rd quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock worth $2,276,000 after buying an additional 5,030 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on ZBH shares. Raymond James lowered their target price on Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Barclays lowered their price objective on shares of Zimmer Biomet from $125.00 to $118.00 and set an “underweight” rating on the stock in a research note on Thursday, December 12th. Evercore ISI cut their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research note on Tuesday, October 1st. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and upped their price target for the company from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, BTIG Research reduced their price objective on Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating for the company in a research note on Thursday, October 3rd. Two analysts have rated the stock with a sell rating, eleven have assigned a hold rating and eight have issued a buy rating to the company. According to data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $123.33.

Zimmer Biomet Trading Up 0.9 %

Zimmer Biomet stock opened at $110.54 on Wednesday. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet Holdings, Inc. has a 12 month low of $100.67 and a 12 month high of $133.90. The company’s fifty day simple moving average is $107.84 and its 200-day simple moving average is $108.04. The stock has a market cap of $22.00 billion, a P/E ratio of 21.02, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, hitting the consensus estimate of $1.74. The company had revenue of $1.82 billion for the quarter, compared to analyst estimates of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The business’s revenue was up 4.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.65 EPS. As a group, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Monday, December 30th will be given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.87%. The ex-dividend date is Monday, December 30th. Zimmer Biomet’s dividend payout ratio is 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.